This method has been reported to effectively bypass the blood-brain barrier (BBB) providing a direct connection of therapeutic proteins including EPO with the Central Nervous System (CNS) to treat neurodegenerative disorders such as Alzheimer’s and stroke while reducing systemic exposure [9, 10]. The gene discussed is EPO; the disease is Stroke.